Total Payments
$53,276
2022 Payments
$3,600
Companies
3
Transactions
25
Payment Breakdown by Category
Research$46,436 (87.2%)
Consulting$6,840 (12.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $46,436 | 21 | 87.2% |
| Consulting Fee | $6,840 | 4 | 12.8% |
Payments by Type
Research
$46,436
21 transactions
General
$6,840
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arbor Pharmaceuticals, Inc. | $27,230 | 14 | $0 (2022) |
| Novartis Pharma AG | $24,246 | 10 | $0 (2021) |
| Azurity Pharmaceuticals, Inc. | $1,800 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $3,600 | 2 | Arbor Pharmaceuticals, Inc. ($1,800) |
| 2021 | $5,076 | 2 | Novartis Pharma AG ($5,076) |
| 2020 | $10,213 | 5 | Novartis Pharma AG ($5,310) |
| 2019 | $9,260 | 4 | Novartis Pharma AG ($5,760) |
| 2018 | $9,588 | 4 | Novartis Pharma AG ($4,950) |
| 2017 | $15,540 | 8 | ARBOR PHARMACEUTICALS, INC. ($12,390) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/20/2022 | Azurity Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 01/20/2022 | Arbor Pharmaceuticals, Inc. | Edarbi (Drug) | Consulting Fee | In-kind items and services | $1,800.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/13/2021 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $2,484.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 08/17/2021 | Novartis Pharma AG | ENTRESTO (Drug) | — | Cash or cash equivalent | $2,592.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 11/20/2020 | Arbor Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| 10/27/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $2,700.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 07/16/2020 | Arbor Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 03/30/2020 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $2,610.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 02/19/2020 | Arbor Pharmaceuticals, Inc. | AR14 (Drug) | — | Cash or cash equivalent | $1,662.50 | Research |
| Study: A Randomized, Double-Blind, Efficacy and Safety Study of AR14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension • Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2019 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $3,060.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 06/05/2019 | Arbor Pharmaceuticals, Inc. | AR14 (Drug) | — | Cash or cash equivalent | $875.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2019 | Novartis Pharma AG | LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) | — | Cash or cash equivalent | $2,700.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 04/03/2019 | Arbor Pharmaceuticals, Inc. | AR14 (Drug) | — | Cash or cash equivalent | $2,625.00 | Research |
| Study: AR 14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 12/14/2018 | Novartis Pharma AG | LCZ696B (Drug) | — | Cash or cash equivalent | $2,430.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 10/03/2018 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,450.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 07/13/2018 | Novartis Pharma AG | LCZ696B (Drug) | — | Cash or cash equivalent | $2,520.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 04/03/2018 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,187.50 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 10/27/2017 | Novartis Pharma AG | LCZ696B (Drug) | — | Cash or cash equivalent | $1,440.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | AR14 (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR 14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | AR14 (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR 14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2017 | ARBOR PHARMACEUTICALS, INC. | Edarbi (Drug) | — | Cash or cash equivalent | $2,065.00 | Research |
| Study: AR14.001 • Category: Cardiology/Vascular Diseases | ||||||
| 08/29/2017 | Novartis Pharma AG | LCZ696B (Drug) | — | Cash or cash equivalent | $1,710.00 | Research |
| Study: CLCZ696B2319 • Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLCZ696B2319 | Novartis Pharma AG | $24,246 | 10 |
| AR14.001 | ARBOR PHARMACEUTICALS, INC. | $12,898 | 6 |
| AR 14.001 | ARBOR PHARMACEUTICALS, INC. | $4,130 | 2 |
| AR 14.001 | Arbor Pharmaceuticals, Inc. | $2,625 | 1 |
| A Randomized, Double-Blind, Efficacy and Safety Study of AR14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension | Arbor Pharmaceuticals, Inc. | $1,663 | 1 |
| AR14.001 | Arbor Pharmaceuticals, Inc. | $875.00 | 1 |
About Dr. Thomas Wells, MD
Dr. Thomas Wells, MD is a Pediatric Nephrology healthcare provider based in Little Rock, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932299591.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Wells, MD has received a total of $53,276 in payments from pharmaceutical and medical device companies, with $3,600 received in 2022. These payments were reported across 25 transactions from 3 companies. The most common payment nature is "" ($46,436).
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location Little Rock, AR
- Active Since 10/13/2006
- Last Updated 10/14/2009
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1932299591
Products in Payments
- Edarbi (Drug) $14,698
- LCZ696B_ENTRESTO_CARDIOVASCULAR (Drug) $11,070
- AR14 (Drug) $9,293
- LCZ696B (Drug) $8,100
- ENTRESTO (Drug) $5,076
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in Little Rock
Saritha Ranabothu, Md, MD
Pediatric Nephrology — Payments: $227.65
Pediatric Nephrology $227.65
Richard Blaszak, Md, MD
Pediatric Nephrology — Payments: $150.00
Pediatric Nephrology $150.00
Mohammed Ilyas, Md, MD
Pediatric Nephrology — Payments: $16.13
Pediatric Nephrology $16.13
Eileen Ellis, Md, MD
Pediatric Nephrology
Pediatric Nephrology
Dr. Brendan Crawford, M.d, M.D
Pediatric Nephrology
Pediatric Nephrology